Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Schizophrenia (February) | 2022

View Archived Issues

Learning Objectives, Schizophrenia, TCPR, February 2022

January 31, 2022

After reading these articles, you should be able to… Read More

An Off-Label Guide to Gabapentin

January 31, 2022

Rajesh R. Tampi, MD, MS, DFAPA. and Chris Aiken, MD.

Off-label gabapentin (Neurontin) got a bad rep when it missed the mark in bipolar disorder, but there may be something worth salvaging in this drug. Here, we weigh its pros and cons for anxiety, substance use disorders, sleep, pain, and hot flashes, and compare it to its underutilized cousin, pregabalin (Lyrica). Read More

Raising the Bar in Schizophrenia Treatment

January 31, 2022

Brian Miller, MD, PhD, MPH

Dr. Miller discusses new options for negative symptoms, how to improve the therapeutic alliance, and what to do when clozapine doesn’t work in schizophrenia. Read More

MDMA-Assisted Therapy for Severe PTSD

January 31, 2022

Michael Posternak, MD.

MDMA is being repurposed as part of drug-assisted psychotherapy for PTSD, and this trial will help determine whether it gains FDA approval for that use. Read More

Lumateperone in Bipolar Depression

January 31, 2022

John C. Raiss, MD.

In December 2021, the FDA approved lumateperone (Caplyta) for bipolar I and II depression, and here we report on one of the trials that led to that approval. Read More

A Novel Treatment for Methamphetamine Use Disorder

January 31, 2022

David A. Moltz, MD.

With so few pharmacologic options for methamphetamine use disorder, a large trial from The New England Journal of Medicine suggest bupropion and naltrexone are worth exploring. Read More

Lybalvi: The Diet Olanzapine

January 31, 2022

Chris Aiken, MD.

Lybalvi hopes to lower the risk of weight gain on olanzapine by combining it with an opioid blocker (samidorphan). But how does it compare to generic options like metformin and naltrexone? Read More